TY - JOUR
T1 - MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq
AU - Minamino, Tetsuo
AU - Yujiri, Toshiaki
AU - Terada, Naohiro
AU - Taffet, George
AU - Michael, Lloyd H.
AU - Johnson, Gary L.
AU - Schneider, Michael D.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002/3/19
Y1 - 2002/3/19
N2 - Signaling via mitogen-activated protein kinases is implicated in heart failure induced by agonists for G protein-coupled receptors that act via the G protein Gαq. However, this assertion relies heavily on pharmacological inhibitors and dominant-interfering proteins and not on gene deletion. Here, we show that endogenous cardiac MAPK/ERK kinase kinase-1 (MEKK1)/(MAP3K1), a mitogen-activated protein kinase kinase kinase, is activated by heart-restricted overexpression of Gαq in mice. In cardiac myocytes derived from embryonic stem cells in culture, homozygous disruption of MEKK1 selectively impaired c-Jun N-terminal kinase activity in the absence or presence of phenlyephrine, a Gαq-dependent agonist. Other terminal mitogen-activated protein kinases were unaffected. In mice, the absence of MEKK1 abolished the increase in cardiac mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-terminal kinase activation by Gαq, and improved ventricular mechanical function. Thus, MEKK1 mediates cardiac hypertrophy induced by Gαq in vivo and is a logical target for drug development in heart disease involving this pathway.
AB - Signaling via mitogen-activated protein kinases is implicated in heart failure induced by agonists for G protein-coupled receptors that act via the G protein Gαq. However, this assertion relies heavily on pharmacological inhibitors and dominant-interfering proteins and not on gene deletion. Here, we show that endogenous cardiac MAPK/ERK kinase kinase-1 (MEKK1)/(MAP3K1), a mitogen-activated protein kinase kinase kinase, is activated by heart-restricted overexpression of Gαq in mice. In cardiac myocytes derived from embryonic stem cells in culture, homozygous disruption of MEKK1 selectively impaired c-Jun N-terminal kinase activity in the absence or presence of phenlyephrine, a Gαq-dependent agonist. Other terminal mitogen-activated protein kinases were unaffected. In mice, the absence of MEKK1 abolished the increase in cardiac mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-terminal kinase activation by Gαq, and improved ventricular mechanical function. Thus, MEKK1 mediates cardiac hypertrophy induced by Gαq in vivo and is a logical target for drug development in heart disease involving this pathway.
UR - http://www.scopus.com/inward/record.url?scp=0037133571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037133571&partnerID=8YFLogxK
U2 - 10.1073/pnas.062453699
DO - 10.1073/pnas.062453699
M3 - Article
C2 - 11891332
AN - SCOPUS:0037133571
VL - 99
SP - 3866
EP - 3871
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 6
ER -